1.150SEK-1.54%Mkt Cap: 161.15M SEKP/E: —Last update: 2026-05-13
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatm…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-1.52
PEG—
P/B0.95
P/S445.16
EV/EBITDA0.15
EV/Revenue-81.71
EPS (TTM)-1.30
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-64.28%
FCF Margin-28614.43%
Operating CF-162.65M SEK
CapEx (TTM)—
Net Debt/EBITDA0.95
Net Debt-190.73M SEK
Technical
SMA 505.414 (-78.8%)
SMA 20010.28 (-88.8%)
Beta2.33
S&P 52W Chg24.23%
Avg Vol (30d)5.70M
Avg Vol (10d)2.16M
Technical Indicators
RSI (14)22.5
MACD-1.2659
MACD Signal-1.6943
MACD Hist.+0.4284
BB Upper1.424 SEK
BB Middle1.196 SEK
BB Lower0.9673 SEK
BB Width38.21%
ATR (14)0.3469 SEK
Vol Ratio (20d)0.30x
52W Range
0.89601% of range17.88
52W High17.88 SEK
52W Low0.8960 SEK
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin-65680.80%
ROE-60.64%
ROA-59.98%
Revenue Growth15.10%
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio4.83
Quick Ratio4.74
Book Value/Sh1.235 SEK
Cash/Share1.387 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.134.00M
Float118.35M
Insiders22.96%
Institutions6.28%
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)1.550 SEK
Target Range1.550 SEK – 1.550 SEK
# Analysts1
Company
Market Cap161.15M SEK
Enterprise Value-29.58M SEK
Revenue (TTM)362.00K SEK
Gross Profit-3.71M SEK
Net Income (TTM)-169.78M SEK
Revenue/Share0.0030 SEK
Fiscal Year EndAug 2025
MR QuarterFeb 2026
Employees41
Last Price1.150 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—